Clinical trials: Portal Hypertension, Noncirrhotic
Portal Hypertension, Budd-Chiari Syndrome
Clinical Diagnosis and Pathological Spectrum of Porto-sinusoidal Vascular Disease in India
There is a need to re-evaluate the patients classified as NCPH and determine whether the new histological classification proposed by the VALDIG applies to the Indian scenario.
- Conditions
- Portal Hypertension, Budd-Chiari Syndrome, Non-Cirrhotic Portal Hypertension, Porto-Sinusoidal Vascular Diseases
- Trial name
- PSVD-India (NCT06054451)
- Where
- India
- Volunteers
- 210 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder)
Pre-emptive Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Cystic Fibrosis Related Liver Disease
Portal hypertension (PHT) and its sequelae are the most clinically important manifestation in cystic fibrosis related liver disease (CFLD), with end-stage liver failure as a late and rare manifestation.
- Conditions
- Cystic Fibrosis Liver Disease, Portal Hypertension Due to Cystic Fibrosis (Disorder), Portal Hypertension, Noncirrhotic
- Trial name
- NCT05037643
- Testing
- TIPS
- Volunteers
- 5 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis, Immunologic Deficiency Syndrome
Natural History of Noncirrhotic Portal Hypertension
Background: Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
- Conditions
- Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis
- Trial name
- NCT02417740
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)